Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.

By H. Janssen, Monika van Zonneveld, H. Senturk, S. Zeuzem, U. Akarca, Y. Çakaloğlu, Christopher Simon, Thomas M K So, G. Gerken, R. de Man and 4 more. The Lancet, 2005

1,195 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/ac7b214d40cbd802f435efa029c41b7ae6a332f3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Y. Liaw
NA Terrault
J. Kao
S. Sarin
N. Leung
A. Lok
T. Piratvisuth
B. McMahon

Citations in the corpus

Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance (2018, background): “TAF joins the list of preferred HBV therapies, along with entecavir, tenofovir disoproxil fumarate (TDF), and peginterferon (peg-IFN; Tables 1 and 2)((6-16)) (section: Updated Recommendations on the Treatment of Patients With Chronic Hepatitis B).”
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update (2015, background): “Combination of Peg-IFN with lamivudine However, in both HBeAg-positive and HBeAg-negative subjects, simultaneous commencement of Peg-IFN and LAM tends to provide a more profound treatment effect on viral suppression without superior sustained virological off-treatment response, compared with Peg-IFN”
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. (2012, background): “The combination of PEG-IFN with lamivudine showed a higher on-treatment virological response but did not show a higher rate of sustained off-treatment virological or serological response [63,64,91].”
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update (2008, result): “These findings were confirmed by recent studies using PegIFN, where HBeAg seroconversion occurred more often in patients with HBV genotypes A (40%–47%) and B (30%– 44%) than those with HBV genotypes C (28%–30%) and D (20%–25%) infection [46, 55].”
EASL Clinical Practice Guidelines: management of chronic hepatitis B. (2009, neutral): “1) [38] [39] [40] [41] [42] [43] [44].”